Doxorubicin and trastuzumab regimen induces biventricular failure in mice

Journal of the American Society of Echocardiography

Volumn 27, Issue 5, 2014, Pages 568-579

  Milano, Giuseppina ^a   Raucci, Angela ^a   Scopece, Alessandro ^a   Daniele, Ranaldi ^a   Guerrini, Uliano ^b   Sironi, Luigi ^a,b   Cardinale, Daniela ^c   Capogrossi, Maurizio C ^d   Pompilio, Giulio ^a,b  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Cardiotoxicity; Echocardiography; Hemodynamics; Mouse model

Indexed keywords

COLLAGEN TYPE 1; DOXORUBICIN; TRASTUZUMAB; TROPONIN I; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HEART VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HEART VENTRICLE WALL; HEART WEIGHT; HEMODYNAMIC PARAMETERS; IMAGING SYSTEM; MOUSE; NONHUMAN; OXIDATIVE STRESS; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ULTRASOUND TRANSDUCER; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; ECHOGRAPHY; FEMALE; HEART VENTRICLE FUNCTION; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; MICE; MICE, INBRED C57BL; VENTRICULAR DYSFUNCTION;

EID: 84899490612     PISSN: 08947317     EISSN: 10976795     Source Type: Journal    
DOI: 10.1016/j.echo.2014.01.014     Document Type: Article

References (42)

1. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., and N.E. Davidson et al. Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
2. G.W. De Keulenaer, K. Doggen, and K. Lemmens The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy Circ Res 106 2010 35 46
3. D.B. Sawyer, C. Zuppinger, T.A. Miller, H.M. Eppenberger, and T.M. Suter Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-ErbB2: potential mechanism for trastuzumab-induced cardiotoxicity Circulation 105 2002 1551 1554 (Pubitemid 34297631)
4. P. Menna, O.G. Paz, M. Chello, E. Covino, E. Salvatorelli, and G. Minotti Anthracycline cardiotoxicity Exp Opin Drug Safety 11 suppl 2012 S21 S36
5. S.A. Crone, Y.Y. Zhao, L. Fan, Y. Gu, S. Minamisawa, and Y. Liu et al. ErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 8 2002 459 465 (Pubitemid 34546747)
6. C. Ozcelik, B. Erdmann, B. Pilz, N. Wettschureck, S. Britsch, and N. Hubner et al. Conditional mutation of the ErbB2 (Her2) receptor in cardiomyocytes leads to dilated cardiomyopathy PNAS 99 2002 8880 8885 (Pubitemid 34693652)
7. T.M. Suter, M. Procter, D.J. van Veldhuisen, M. Muscholl, J. Bergh, and C. Carlomagno et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial J Clin Oncol 25 2007 3859 3865 (Pubitemid 47477261)
8. E.H. Romond, J.H. Jeong, P. Rastogi, S.M. Swain, C.E. Geyer Jr., and M.S. Ewer et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 30 2012 3792 3799
9. S.D. Russell, K.L. Blackwell, J. Lawrence, J.E. Pippen Jr., M.T. Roe, and F. Wood et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials J Clin Oncol 28 2010 3416 3421
10. E.J. Bowles, R. Wellman, H.S. Feigelson, A.A. Onitilo, A.N. Freedman, and T. Delate et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study J Natl Cancer Inst 104 2012 1293 1305
11. J.R. Mackey, M. Clemons, M.A. Cote, D. Delgado, S. Dent, and A. Paterson et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group Curr Oncol 15 2008 24 35
12. J.R. Walker, A. Sharma, M. Lytwyn, S. Bohonis, J. Thliveris, and P.K. Singal et al. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity J Am Soc Echocardiogr 24 2011 699 705
13. D.S. Jassal, S.Y. Han, C. Hans, A. Sharma, T. Fang, and R. Ahmadie et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy J Am Soc Echocardiogr 22 2009 418 424
14. F. Seta, M. Rahmani, P.V. Turner, and C.D. Funk Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline PLoS One 6 2011 e23439
15. D. Urboniene, I. Haber, Y.H. Fang, T. Thenappan, and S.L. Archer Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension Am J Physiol 299 2010 L401 L412
16. G. Hansmann, A. Fernandez-Gonzalez, M. Aslam, S.H. Vitali, T. Martin, and S.A. Mitsialis et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension Pulm Circ 2 2012 170 181
17. L. Ciuclan, O. Bonneau, M. Hussey, N. Duggan, A.M. Holmes, and R. Good et al. A novel murine model of severe pulmonary arterial hypertension Am J Respir Crit Care Med 184 2011 1171 1182
18. D.M. Weinstein, M.J. Mihm, and J.A. Bauer Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice J Pharmacol Exp Ther 294 2000 396 401 (Pubitemid 30434713)
19. P. Pacher, T. Nagayama, P. Mukhopadhyay, S. Batkai, and D.A. Kass Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats Nat Prot 3 2008 1422 1434
20. D. Georgakopoulos, W.A. Mitzner, C.H. Chen, B.J. Byrne, H.D. Millar, and J.M. Hare et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry Am J Phys 274 1998 H1416 H1422
21. D.M. Tabima, T.A. Hacker, and N.C. Chesler Measuring right ventricular function in the normal and hypertensive mouse hearts using admittance-derived pressure-volume loops Am J Physiol 299 2010 H2069 H2075
22. M.A. Borgdorff, B. Bartelds, M.G. Dickinson, B. Boersma, M. Weij, and A. Zandvoort et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle Eur J Heart Fail 14 2012 1067 1074
23. Y. Hua, Y. Zhang, A.F. Ceylan-Isik, L.E. Wold, J.M. Nunn, and J. Ren Chronic AKT activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy Basic Res Cardiol 106 2011 1173 1191
24. C. Faul, A.P. Amaral, B. Oskouei, M.C. Hu, A. Sloan, and T. Isakova et al. FGF23 induces left ventricular hypertrophy J Clin Invest 121 2011 4393 4408
25. G. Riccio, G. Esposito, E. Leoncini, R. Contu, G. Condorelli, and M. Chiariello et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents FASEB J 23 2009 3171 3178
26. J. Huelsenbeck, C. Henninger, A. Schad, K.J. Lackner, B. Kaina, and G. Fritz Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity Cell Death Dis 2 2011 e190
27. P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, and L. Liaudet et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro Am J Physiol 296 2009 H1466 H1483
28. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
29. M.A. Owens, B.C. Horten, and M.M. Da Silva Her2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 2004 63 69 (Pubitemid 38821193)
30. E. de Azambuja, P.L. Bedard, T. Suter, and M. Piccart-Gebhart Cardiac toxicity with anti-Her-2 therapies: what have we learned so far? Target Oncol 4 2009 77 88
31. P. Mukhopadhyay, M. Rajesh, S. Batkai, V. Patel, Y. Kashiwaya, and L. Liaudet et al. Cb1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes Cardiovasc Res 85 2010 773 784
32. M.S. Ewer, and S.M. Ewer Cardiotoxicity of anticancer treatments: what the cardiologist needs to know Nat Rev Cardiol 7 2010 564 575
33. M.L. Telli, S.A. Hunt, R.W. Carlson, and A.E. Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533 (Pubitemid 47310891)
34. S.A. Lange, B. Ebner, A. Wess, M. Kogel, M. Gajda, and T. Hitschold et al. Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy Clin Res Cardiol 101 2012 415 426
35. A. Tanindi, U. Demirci, G. Tacoy, S. Buyukberber, Y. Alsancak, and U. Coskun et al. Assessment of right ventricular functions during cancer chemotherapy Eur J Echocardiogr 12 2011 834 840
36. D. Cardinale, M.T. Sandri, A. Colombo, N. Colombo, M. Boeri, and G. Lamantia et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754 (Pubitemid 38737923)
37. F. Dodos, T. Halbsguth, E. Erdmann, and U.C. Hoppe Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults Clin Res Cardiol 97 2008 318 326 (Pubitemid 351725058)
38. P. Mathew, W. Suarez, K. Kip, E. Bayar, R. Jasty, Y. Matloub, and D. Raisch Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study Cancer Invest 19 2001 352 359 (Pubitemid 32525183)
39. D. Cardinale, A. Colombo, R. Torrisi, M.T. Sandri, M. Civelli, and M. Salvatici et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
40. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity Eur J Cancer 43 2007 2046 2051 (Pubitemid 47380360)
41. K. Gabrielson, D. Bedja, S. Pin, A. Tsao, L. Gama, and B. Yuan et al. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury Cancer Res 67 2007 1436 1441 (Pubitemid 46383368)
42. Y. Zhao, D. McLaughlin, E. Robinson, A.P. Harvey, M.B. Hookham, and A.M. Shah et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy Cancer Res 70 2010 9287 9297